• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    HeartSciences Inc. - Warrant (NQ:HSCSW)

    0.0600 UNCHANGED
    Streaming Delayed Price Updated: 10:31 AM EDT, Jun 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.0600
    Bid (Size) 0.0360 (100)
    Ask (Size) 0.0698 (400)
    Prev. Close 0.0600
    Today's Range 0.0600 - 0.0600
    52wk Range 0.0350 - 0.2000
    Shares Outstanding 10,362,284
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
    Bunkerhill Health’s FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences’... 
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
    Agreement follows Cibolo Health’s endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences’ ECG management platform 
    From HeartSciences Inc.
    Via GlobeNewswire

    Performance

    YTD
    -22.6%
    -22.6%
    1 Month
    -1.0%
    -1.0%
    3 Month
    -15.0%
    -15.0%
    6 Month
    +71.4%
    +71.4%
    1 Year
    -3.2%
    -3.2%

    More News

    Read More
    News headline image
    HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces Conference Participation and Investor Webinar
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is HeartSciences Inc. - Warrant publicly traded?
    Yes, HeartSciences Inc. - Warrant is publicly traded.
    What exchange does HeartSciences Inc. - Warrant trade on?
    HeartSciences Inc. - Warrant trades on the Nasdaq Stock Market
    What is the ticker symbol for HeartSciences Inc. - Warrant?
    The ticker symbol for HeartSciences Inc. - Warrant is HSCSW on the Nasdaq Stock Market
    What is the current price of HeartSciences Inc. - Warrant?
    The current price of HeartSciences Inc. - Warrant is 0.0600
    When was HeartSciences Inc. - Warrant last traded?
    The last trade of HeartSciences Inc. - Warrant was at 06/03/26 10:31 AM ET
    What is the market capitalization of HeartSciences Inc. - Warrant?
    The market capitalization of HeartSciences Inc. - Warrant is 621.74K
    How many shares of HeartSciences Inc. - Warrant are outstanding?
    HeartSciences Inc. - Warrant has 622K shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.